Zegerid Otc is a drug owned by Riley Consumer Care Llc Dba Carlin Consumer Health. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 15, 2016. Details of Zegerid Otc's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6489346 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(8 years ago) |
Expired
|
| US7399772 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(8 years ago) |
Expired
|
| US6699885 | Substituted benzimidazole dosage forms and methods of using same |
Jul, 2016
(8 years ago) |
Expired
|
| US6645988 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(8 years ago) |
Expired
|
| US5840737 | Omeprazole solution and method for using same |
Jul, 2016
(8 years ago) |
Expired
|
| US6780882 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zegerid Otc's patents.
Latest Legal Activities on Zegerid Otc's Patents
Given below is the list of recent legal activities going on the following patents of Zegerid Otc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Correspondence Address Change Critical | 03 Nov, 2005 | US6780882 |
| Correspondence Address Change Critical | 28 Oct, 2005 | US6780882 |
| File Marked Found | 23 Mar, 2005 | US6780882 |
| Correspondence Address Change Critical | 11 Mar, 2005 | US6780882 |
| File Marked Lost | 04 Mar, 2005 | US6780882 |
| Correspondence Address Change Critical | 11 Nov, 2004 | US6780882 |
| Correspondence Address Change Critical | 27 Oct, 2004 | US6780882 |
| Patent Issue Date Used in PTA Calculation Critical | 24 Aug, 2004 | US6780882 |
| Recordation of Patent Grant Mailed Critical | 24 Aug, 2004 | US6780882 |
| Issue Notification Mailed Critical | 05 Aug, 2004 | US6780882 |
US patents provide insights into the exclusivity only within the United States, but Zegerid Otc is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zegerid Otc's family patents as well as insights into ongoing legal events on those patents.
Zegerid Otc's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zegerid Otc's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 15, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zegerid Otc Generic API suppliers:
Omeprazole; Sodium Bicarbonate is the generic name for the brand Zegerid Otc. 11 different companies have already filed for the generic of Zegerid Otc, with Strides Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zegerid Otc's generic
How can I launch a generic of Zegerid Otc before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Zegerid Otc's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Zegerid Otc's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Zegerid Otc -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 20 mg/1100 mg | 20 Apr, 2010 | 1 | 15 Jul, 2016 | 16 Jul, 2016 | Extinguished |
Alternative Brands for Zegerid Otc
Zegerid Otc which is used for treating frequent heartburn., has several other brand drugs using the same active ingredient (Omeprazole; Sodium Bicarbonate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Azurity |
| ||
| Salix |
| ||
| Santarus |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Omeprazole; Sodium Bicarbonate, Zegerid Otc's active ingredient. Check the complete list of approved generic manufacturers for Zegerid Otc
About Zegerid Otc
Zegerid Otc is a drug owned by Riley Consumer Care Llc Dba Carlin Consumer Health. It is used for treating frequent heartburn. Zegerid Otc uses Omeprazole; Sodium Bicarbonate as an active ingredient. Zegerid Otc was launched by Riley Consumer in 2009.
Approval Date:
Zegerid Otc was approved by FDA for market use on 01 December, 2009.
Active Ingredient:
Zegerid Otc uses Omeprazole; Sodium Bicarbonate as the active ingredient. Check out other Drugs and Companies using Omeprazole; Sodium Bicarbonate ingredient
Treatment:
Zegerid Otc is used for treating frequent heartburn.
Dosage:
Zegerid Otc is available in the following dosage forms - capsule form for oral use, for suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG;1.1GM | CAPSULE | Over the counter | ORAL |
| 20MG/PACKET;1.68GM/PACKET | FOR SUSPENSION | Over the counter | ORAL |